Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS4BUK)

Drug Name

TG-1042 Drug Info

Synonyms

TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Discontinued in Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMS4BUK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interferon-gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emapalumab	DMZG5WL	Primary haemophagocytic lymphohistiocytosis	4A01.23	Approved	[3]
Fumaric acid	DMP83UZ	Multiple sclerosis	8A40	Phase 3	[4]
VIR-201	DMAMIU4	Human immunodeficiency virus infection	1C62	Phase 1/2	[5]
CIGB-128	DMB2MKU	Basal cell carcinoma	2C32	Phase 1	[6]
AMG 811	DMEIMBP	Discoid lupus erythematosus	EB51.0	Phase 1	[7]
CRx-191	DMB9QSJ	Psoriatic disorder	EA90	Discontinued in Phase 2	[8]
TAK-603	DMN1YHP	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[9]
Fontolizumab	DMEH6LV	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[10]
VPM-4-001	DMZHAVG	Prostate cancer	2C82.0	Preclinical	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-gamma (IFNG)	TT93WF5	IFNG_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010265)
2	Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
5	EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
6	Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
7	Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
8	CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
9	T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
10	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
11	BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.